Extensive macular atrophy with pseudodrusen (EMAP) is a relatively newly proposed clinical entity that was first reported in 2009. Although no definitive diagnostic criteria have been defined. characteristic findings can distinguish it from other diseases. especially dry age-related macular dystrophy (AMD). https://www.roneverhart.com/Ben-Nye-Luxury-Powder-Cameo/